Triple negative breast cancer (TNBC) remains one of the most formidable challenges in modern oncology. Characterized by its aggressive nature and a frustrating lack of hormonal or HER2-driven targets, it leaves many patients with limited therapeutic pathways beyond the traditional, often debilitating, combination of surgery and chemotherapy. However, a pioneering research project at King’s College London, funded by the charity Breast Cancer Now, is shifting the focus toward an unlikely culprit: a common, essential mineral.
Researchers are now investigating the role of copper in the progression of TNBC, exploring whether sequestering this micronutrient could serve as a novel therapeutic strategy to stop the disease from spreading—a breakthrough that could redefine the standard of care for thousands.
Main Facts: The Copper-Cancer Connection
Copper is a vital trace element necessary for human life, playing a crucial role in iron absorption, nerve function, and immune system support. Yet, in the context of oncology, this same essential mineral can take on a darker role. Emerging evidence suggests that cancer cells, particularly those found in triple negative breast cancer, exhibit a heightened dependency on copper to fuel their rapid proliferation and metastatic potential.
TNBC accounts for approximately 15% of all breast cancer diagnoses. It earns its name from the absence of three common receptors—estrogen, progesterone, and HER2—which are typically used as "targets" for precision therapies like hormone therapy or Herceptin. Because these receptors are absent, standard targeted treatments are ineffective. Consequently, patients often face a narrower window of treatment, relying heavily on systemic chemotherapy, which, while effective at killing cancer cells, can cause significant damage to healthy tissues.
The research project, led by Dr. Cinzia Imberti at King’s College London, has been awarded £169,966 in funding to determine if the drug tetrathiomolybdate (TTM) can disrupt the biological mechanisms that allow TNBC to thrive. TTM is an "anti-copper" agent that works by chelating, or binding to, copper in the body, effectively lowering its availability. If the team can prove that copper-depletion halts the spread of these specific cancer cells, it could introduce a far less toxic, highly specific treatment modality into the oncologist’s toolkit.
Chronology: A Path to Discovery
The scientific journey toward understanding the metal-cancer interface has been incremental. For years, the scientific community has noted that copper levels are often elevated in the serum of cancer patients. However, only recently has the focus turned toward the intracellular mechanics of how tumors manipulate this mineral.
- Initial Observations: Early studies identified that copper plays a catalytic role in the formation of new blood vessels (angiogenesis), which tumors require to grow.
- The TTM Clinical Potential: Tetrathiomolybdate was originally developed to treat Wilson’s disease, a rare genetic disorder where the body cannot properly process copper, leading to toxic accumulation. Clinical observations indicated that patients on TTM therapy for copper-related conditions showed unusual physiological responses that hinted at anti-cancer activity.
- 2024 Research Grant: Following preliminary findings that suggested TTM could inhibit the progression of triple negative cells, Breast Cancer Now awarded the grant to Dr. Imberti’s team at King’s College London.
- Current Phase: The team is now moving into the experimental phase, utilizing advanced medical imaging to visualize the "copper footprint" within TNBC cells. This phase is designed to map exactly how these cells sequester the mineral and what specific cellular processes are deactivated when that supply is cut off.
Supporting Data: Why Triple Negative Matters
The urgency of this research is underscored by the clinical reality of the disease. In the UK alone, approximately 8,000 women are diagnosed with TNBC annually. The biology of the disease is inherently volatile; it is statistically more likely to return or metastasize—spreading to the lungs, liver, or brain—within the first three to five years post-treatment than other breast cancer subtypes.
The reliance on chemotherapy presents a significant hurdle. While "effective" by clinical standards, the systemic nature of the treatment means that patients frequently endure long-term side effects, including peripheral neuropathy, cardiac issues, and significant fatigue, all of which compromise quality of life.
The mechanism of TTM is unique. By binding to copper, it prevents the mineral from participating in the signaling pathways that cancer cells use to migrate. If the researchers can confirm this mechanism, the secondary advantage is the potential for non-invasive monitoring. Dr. Imberti’s team is exploring whether standard medical imaging can track the depletion of copper within the tumor, providing doctors with a "real-time" dashboard of treatment efficacy.
Official Responses: A Collaborative Hope
The research has garnered significant support from the scientific and patient advocacy communities, both of whom view this as a pivotal moment in the fight against aggressive breast cancer.
Dr. Cinzia Imberti, the lead investigator from King’s College London, emphasized the importance of this specific research avenue:
"We need new treatments for triple negative breast cancer. From what we know already, focusing our attention on copper and how triple negative breast cancer cells use it is a promising avenue to explore. We hope that this research will get us one step closer to preventing this type of breast cancer from spreading."
Dr. Simon Vincent, Chief Scientific Officer at Breast Cancer Now, underscored the institutional commitment to this project:
"Each year around 8,000 UK women are diagnosed with triple negative breast cancer, which can be harder to treat and is more likely to return or spread soon after treatment. That’s why Breast Cancer Now is funding this research, which could lead to new ways to treat the disease and open the door to more personalised treatments. Research like this brings us closer to a future where people diagnosed with triple negative breast cancer have more treatment options and better chances of living well, without the fear of their disease coming back."
The Human Element: A Patient’s Perspective
Statistics, while vital, only tell part of the story. For Sarah Hutchinson, a 29-year-old from Sunderland diagnosed with TNBC in 2024, the research represents a hope for a future where the treatment is not as traumatic as the disease itself.
Sarah’s story is a sobering reminder of the impact of the current treatment standard. Diagnosed when her twins were just toddlers, she endured 16 rounds of chemotherapy, immunotherapy, and a double mastectomy within a six-month window.
"I had no idea there were so many different types of breast cancer or so many different treatment options," Sarah shared. "Chemotherapy felt like my only option, and I experienced really challenging side effects, which took a huge toll on me. It’s really encouraging to know so much research is happening, and I hope it leads to more treatment options for people with triple negative breast cancer in the near future."
For Sarah, and many others, the prospect of a targeted, less toxic intervention is not just a scientific milestone—it is a lifeline.
Implications: The Future of Oncology
The implications of Dr. Imberti’s work extend far beyond the laboratory. If successful, the repurposing of TTM for TNBC could represent a "paradigm shift" in how oncologists approach "hard-to-treat" cancers.
- Repurposed Drugs: Utilizing an existing, FDA-approved drug (TTM) could significantly shorten the timeline to clinical adoption compared to developing a brand-new molecule from scratch.
- Personalized Imaging: If researchers can successfully use imaging to track copper depletion, it moves the field toward "theranostics"—a combination of therapy and diagnostics—where the treatment is adjusted based on how the patient’s individual tumor responds at the molecular level.
- Metastatic Prevention: Perhaps most importantly, the focus on stopping the "spread" addresses the most lethal aspect of the disease. If copper-targeting can lock the tumor in place, it could prevent the disease from becoming metastatic, which is currently the point at which breast cancer transitions from being treatable to incurable.
As the team at King’s College London continues their work, the scientific community remains cautiously optimistic. By unraveling the role of one of the body’s most basic minerals, researchers may well have found the key to silencing one of the most aggressive cancers of the modern era. The road from the lab bench to the clinic is long, but for patients like Sarah, the progress is both timely and essential.
About the Author
